Drugs / human Wharton jelly-derived mesenchymal stem cells
human Wharton jelly-derived mesenchymal stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03684122 | Jun 2018 → Jul 2020 | Parkinson disease | University of Jordan | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human Wharton jelly-derived mesenchymal stem cells | “OBJECTIVE: This protocol aims to examine the safety and therapeutic benefit of human Wharton jelly-derived mesenchymal stem cells (WJ-MScs) and their derivatives, neuronal stem...” PMID 34677138 ↗ Oct 2021 |
| Known as | mesenchymal stem cells | “OBJECTIVE: This protocol aims to examine the safety and therapeutic benefit of human Wharton jelly-derived mesenchymal stem cells (WJ-MScs) and their derivatives, neuronal stem...” PMID 34677138 ↗ Oct 2021 |
| Known as | MSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03684122 ↗ |
| Known as | WJ-MScs | “OBJECTIVE: This protocol aims to examine the safety and therapeutic benefit of human Wharton jelly-derived mesenchymal stem cells (WJ-MScs) and their derivatives, neuronal stem...” PMID 34677138 ↗ Oct 2021 |
| Modality | Cell therapy | “The tailored comprehensive and scaled TEAEs and the variety of evaluation tools used enables a comprehensive assessment of this cellular therapy treatment protocol.” PMID 34677138 ↗ Oct 2021 |
| Route | Intrathecal | “Allogenic Umbilical Cord derived stem cells (MSCs) differentiated into neural stem cells (NSCs) injected intrathecaly and intravenously to enrolled PD patients.” NCT03684122 ↗ |
| Route | Intravenous | “Allogenic Umbilical Cord derived stem cells (MSCs) differentiated into neural stem cells (NSCs) injected intrathecaly and intravenously to enrolled PD patients.” NCT03684122 ↗ |